Literature DB >> 30002201

Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database.

Masanori Arai1, Jun Shirakawa2, Hiromi Konishi1, Naoko Sagawa1, Yasuo Terauchi2.   

Abstract

Entities:  

Year:  2018        PMID： 30002201     DOI： 10.2337/dc18-0210

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  12 in total

1.  Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.

Authors:  Arata Hibi; Yuto Kasahara; Yoshitaka Ishihara; Koichi Hata; Norihisa Hosokawa; Takahiko Nakagawa
Journal:  CEN Case Rep       Date:  2020-01-28

Review 2.  Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.

Authors:  Hideyuki Ujiie; David Rosmarin; Michael P Schön; Sonja Ständer; Katharina Boch; Martin Metz; Marcus Maurer; Diamant Thaci; Enno Schmidt; Connor Cole; Kyle T Amber; Dario Didona; Michael Hertl; Andreas Recke; Hanna Graßhoff; Alexander Hackel; Anja Schumann; Gabriela Riemekasten; Katja Bieber; Gant Sprow; Joshua Dan; Detlef Zillikens; Tanya Sezin; Angela M Christiano; Kerstin Wolk; Robert Sabat; Khalaf Kridin; Victoria P Werth; Ralf J Ludwig
Journal:  Front Med (Lausanne)       Date:  2022-06-09

3.  Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid.

Authors:  Ágnes Kinyó; Anita Hanyecz; Zsuzsanna Lengyel; Dalma Várszegi; Péter Oláh; Csaba Gyömörei; Endre Kálmán; Tímea Berki; Rolland Gyulai
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

4.  Potential linkage between dipeptidyl peptidase-4 inhibitor use and the risk of pancreatitis/pancreatic cancer.

Authors:  Jun Shirakawa; Yasuo Terauchi
Journal:  J Diabetes Investig       Date:  2020-01-07       Impact factor: 4.232

Review 5.  Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.

Authors:  Kaisa Tasanen; Outi Varpuluoma; Wataru Nishie
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 8.786

6.  Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.

Authors:  Yosuke Mai; Wataru Nishie; Kentaro Izumi; Hiroshi Shimizu
Journal:  Front Immunol       Date:  2019-05-29       Impact factor: 7.561

7.  Ceritinib-associated hyperglycemia in the Japanese Adverse Drug Event Report Database.

Authors:  Haruka Fujita; Takaaki Murakami; Fumiaki Tomoike; Daisuke Yabe; Nobuya Inagaki
Journal:  J Diabetes Investig       Date:  2019-11-29       Impact factor: 4.232

Review 8.  Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus.

Authors:  Kohei Kaku; Koichi Kisanuki; Mari Shibata; Takashi Oohira
Journal:  Drug Saf       Date:  2019-11       Impact factor: 5.606

Review 9.  Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.

Authors:  Shiying Shao; QinQin Xu; Xuefeng Yu; Ruping Pan; Yong Chen
Journal:  Pharmacol Ther       Date:  2020-02-14       Impact factor: 12.310

10.  Bullous pemphigoid associated with the use of dipeptidil peptidase-4 inhibitors: analysis from studies based on pharmacovigilance databases.

Authors:  Juan A Molina-Guarneros; María Sainz-Gil; Rosario Sanz-Fadrique; Pilar García; Pedro Rodríguez-Jiménez; Ester Navarro-García; Luis H Martin
Journal:  Int J Clin Pharm       Date:  2020-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.